Lin Chih-Hsien, Lin Chin-Yu, Chung Fa-Po, Lin Yenn-Jiang, Chang Shih-Lin, Lo Li-Wei, Hu Yu-Feng, Chao Tze-Fan, Liao Jo-Nan, Chang Ting-Yung, Tuan Ta-Chuan, Kuo Ling, Wu Cheng-I, Liu Chih-Min, Liu Shin-Huei, Li Guan-Yi, Kuo Ming-Jen, Weng Chi-Jen, Chen Shih-Ann
Division of Cardiology, Department of Internal Medicine, Chi-Mei Medical Center, Tainan, Taiwan.
Heart Rhythm Center, Taipei Veterans General Hospital, Taipei, Taiwan.
Front Cardiovasc Med. 2023 May 12;10:1135230. doi: 10.3389/fcvm.2023.1135230. eCollection 2023.
Catheter ablation (CA) is a treatment strategy for atrial fibrillation (AF) in patients with hypertrophic cardiomyopathy (HCM). We investigated the electrophysiological characteristics of recurrence in a tertiary referral center and compared long-term clinical outcomes after CA therapy with patients who did not undergo CA.
Patients with HCM and AF who underwent CA (group 1, = 60) or pharmacological treatment (group 2, = 298) between 2006 and 2021 were enrolled in this study. The baseline characteristics and electrophysiological characteristics of group 1 patients were examined to elucidate the reason for the recurrence of AF after CA therapy. The clinical results of the patients in Group 1 and Group 2 were compared using a propensity score (PS)-matched method.
The most common cause of recurrence was pulmonary vein reconnection (86.5%), followed by non-pulmonary vein triggers (40.5%), cavotricuspid isthmus flutter (29.7%), and atypical flutter (24.3%). Thyroid disease (HR, 14.713; < 0.01), diabetes (HR, 3.074; = 0.03), and non-paroxysmal AF (HR, 4.012; = 0.01); these factors independently predicted recurrence. After the first recurrence, patients who underwent repeat CA showed a better arrhythmia-free state (74.1%) than those who underwent drug escalation therapy (29.4%, < 0.01). After matching, PS-group 1 patients showed significantly better outcomes in all-cause mortality, heart failure hospitalization, and left atrial reverse remodeling than PS-group 2 patients.
Patients who underwent CA showed better clinical outcomes than those who underwent drug therapy. The main predictors of recurrence were thyroid disease, diabetes, and non-paroxysmal AF.
导管消融术(CA)是肥厚型心肌病(HCM)患者心房颤动(AF)的一种治疗策略。我们在一家三级转诊中心研究了复发的电生理特征,并比较了CA治疗与未接受CA治疗患者的长期临床结局。
纳入2006年至2021年间接受CA治疗的HCM合并AF患者(第1组,n = 60)或接受药物治疗的患者(第2组,n = 298)。检查第1组患者的基线特征和电生理特征,以阐明CA治疗后AF复发的原因。使用倾向评分(PS)匹配法比较第1组和第2组患者的临床结果。
复发的最常见原因是肺静脉重新连接(86.5%),其次是非肺静脉触发因素(40.5%)、腔静脉峡部扑动(29.7%)和非典型扑动(24.3%)。甲状腺疾病(HR,14.713;P < 0.01)、糖尿病(HR,3.074;P = 0.03)和非阵发性AF(HR,4.012;P = 0.01);这些因素独立预测复发。首次复发后,接受重复CA治疗的患者无心律失常状态(74.1%)优于接受药物升级治疗的患者(29.4%,P < 0.01)。匹配后,PS-第1组患者在全因死亡率、心力衰竭住院率和左心房逆向重构方面的结局明显优于PS-第2组患者。
接受CA治疗的患者临床结局优于接受药物治疗的患者。复发的主要预测因素是甲状腺疾病、糖尿病和非阵发性AF。